A South Korean biotech and a Boston medical center are using AI to analyze MRI scans and predict how individual Alzheimer's patients will respond to treatment. NeuroXT's technology scans for subtle brain patterns typically requiring expensive PET imaging, then extracts similar insights from widely available MRIs. The expanded collaboration will study over a year of patient treatment data from BIDMC to identify imaging biomarkers linked to treatment response. The goal is to shift Alzheimer's care from a one-size-fits-all model toward personalized medicine — similar to how cancer treatment is now tailored to individual patients. This could help doctors decide who to treat, when to start, and which therapy to use.
